Brainsway Ltd. wins Israeli Ministry of Health approval for its non-invasive deep-brain stimulation device, which uses transcranial magnetic stimulation to treat depression, bipolar disorder and schizophrenia.
Brainsway Ltd.'s transcranial magnetic stimulation device won Israeli Ministry of Health approval to treat major depression, bipolar disorder and negative impairment in schizophrenia patients.
The approval clears Jerusalem-based Brainsway to sell the non-invasive TMS device, which delivers brief magnetic pulses to the brain, to four medical centers specializing in mental disorders.
"We are very pleased to receive this vote of confidence in the Deep TMS technology from our homeland's regulatory authority. We are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that we've already received in Europe," CEO Uzi Sofer said in prepared remarks.